Novo Nordisk to acquire ocedurenone for uncontrolled hypertension from KBP Biosciences
Novo Nordisk A/S and KBP Biosciences PTE., Ltd. announced that Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular…
Read More...
Read More...
